Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04121221 · ClinicalTrials.gov registry record · Phase 3
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Mapi Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,016
- Enrollment target
- 20
- Study locations
NCT04121221: Completed Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Mapi Pharma.
NCT04121221 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Mapi Pharma. The registered enrollment target is 1,016 participants, above the 528-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04121221, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Mapi Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,016 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks
Primary Outcome
ARR during the 52 weeks of the PC period as derived from the total number of confirmed relapses
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GA Depot
Study Locations (20)
Other
- Mapi Pharma Research site 02 - Homyel
- Mapi Pharma Research site 04 - Minsk
- Mapi Pharma Research site 05 - Minsk
- Mapi Pharma Research site 06 - Minsk
- Mapi Pharma Research site 01 - Vitebsk
- Mapi Pharma Research site 07 - Vitebsk
- Mapi Pharma Research site 04 - Banja Luka
- Mapi Pharma Research site 06 - Bihać
- Mapi Pharma Research site 01 - Sarajevo
Alabama
- Mapi Pharma Research site 08 - Birmingham
- Mapi Pharma Research site 11 - Cullman
Florida
- Mapi Pharma Research site 17 - Homestead
- Mapi Pharma Research site 09 - Miami
California
- Mapi Pharma Research site 15 - Pasadena
Colorado
- Mapi Pharma Research site 14 - Denver
District of Columbia
- Mapi Pharma Research site 12 - Washington D.C.
Illinois
- Mapi Pharma Research site 01 - Northbrook
Michigan
- Mapi Pharma Research site 02 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,016 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 3 |
What the finished NCT04121221 record still lists
NCT04121221 is an interventional study that assigns participants to a tested intervention. Its 1,016 participants enrollment target places it among the larger protocols in the corpus, above the 528-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04121221 names 20 study sites across 10 states, led by Other, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT04121221 about?
NCT04121221 is a clinical study titled "A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS". A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once ev...
What is the current status of trial NCT04121221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,016 participants. The study started on 2019-09-19. Estimated completion is 2023-06-13.
What conditions does trial NCT04121221 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT04121221?
The interventions under investigation include: Placebo (OTHER), GA Depot (DRUG).
Who is sponsoring clinical trial NCT04121221?
This trial is sponsored by Mapi Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04121221 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04121221's enrollment target sits among peer trials
1,016 3rd of 29 higher than 27 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
COMPLETED · Phase 3
-
ACTH for Fatigue in Multiple Sclerosis Patients
COMPLETED · Phase 3
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI